Travere Therapeutics (TVTX) is in focus after the FDA granted full approval to FILSPARI to reduce proteinuria in adults and children with focal segmental glomerulosclerosis without nephrotic syndrome, the first authorized treatment for this rare kidney disorder.

The FDA approval headlines arrive alongside strong price momentum, with a 7 day share price return of 40.78% and a 30 day return of 51.22%. The 1 year total shareholder return of 173.26% suggests that interest has been building over a longer period.

If you are looking for other potential opportunities in high growth areas of healthcare, this is a good moment to broaden your search with 35 healthcare AI stocks

With Travere now holding full FDA approval for FILSPARI in a second rare kidney disease and the share price up sharply, is TVTX still trading at a discount, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 4.1% Undervalued

Travere Therapeutics most followed narrative points to a fair value of $42.50 versus the last close at $40.77, framing today’s price as slightly below that estimate while highlighting how much depends on FILSPARI’s expansion.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market. If approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

Want to see how this rare disease thesis translates into numbers? The narrative leans on rapid revenue compounding, margin expansion, and a richer future earnings multiple.

Result: Fair Value of $42.50 (UNDERVALUED)

However, execution is not risk free, with Travere heavily tied to FILSPARI at a time when competition, pricing pressure, and ongoing R&D and SG&A costs remain significant.

Next Steps

With the optimism around FILSPARI and the clear execution risks laid out, this is a moment to look at the full picture yourself and act decisively by weighing up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop with just one opportunity, you might miss other setups that fit your style. Use the Simply Wall St Screener to quickly scan for focused ideas.

• Target potential upside by reviewing companies that combine quality fundamentals with appealing valuations through the 59 high quality undervalued stocks.
• Prioritize resilience by checking out the 70 resilient stocks with low risk scores and see which companies score well on stability and downside protection.
• Hunt for future market leaders before the crowd notices by using the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.